Search Results

AMX0035 Approved

AMX0035 Approved

WEBINAR: AMX0035 Results - Implications for People with ALS

WEBINAR: AMX0035 Results - Implications for People with ALS

Community Conversation: AMX0035 in the FDA’s Approval Process

Community Conversation: AMX0035 in the FDA’s Approval Process

Treatment updates in ALS: edaravone, AMX0035, and tofersen

Treatment updates in ALS: edaravone, AMX0035, and tofersen

#ApproveAMX0035

#ApproveAMX0035

Sabrina Paganoni, MD, PhD: AMX0035 and the Future of ALS Care

Sabrina Paganoni, MD, PhD: AMX0035 and the Future of ALS Care

Oral Testimony to the FDA Advisory Committee on the Approval of AMX0035

Oral Testimony to the FDA Advisory Committee on the Approval of AMX0035

AMX0035 in ALS: long-term survival analysis of the CENTAUR trial

AMX0035 in ALS: long-term survival analysis of the CENTAUR trial

Amylyx Pharmaceuticals' AMX0035 for ALS receives negative CHMP opinion

Amylyx Pharmaceuticals' AMX0035 for ALS receives negative CHMP opinion

AMX0035 Research Update 19OCT20

AMX0035 Research Update 19OCT20

Sabrina Paganoni, MD, PhD: AMX0035 and the Current ALS Treatment Landscape

Sabrina Paganoni, MD, PhD: AMX0035 and the Current ALS Treatment Landscape

Dr. Merit Cudkovickz testimony in Congress for NurOwn and AMX0035 approval, as well as FDA changes.

Dr. Merit Cudkovickz testimony in Congress for NurOwn and AMX0035 approval, as well as FDA changes.